Status:
COMPLETED
Incidence of Hyperpigmentation in Black Patients With Multiple Myeloma Treated With Immunomodulatory Drugs
Lead Sponsor:
Bristol-Myers Squibb
Conditions:
Multiple Myeloma
Eligibility:
All Genders
18+ years
Brief Summary
The purpose of this study is to measure the incidence of hyperpigmentation in Black participants with multiple myeloma (MM) treated with immunomodulatory drugs (IMiDs) compared with Black participants...
Eligibility Criteria
Inclusion
- Participants ≥18 years of age at index date
- Participants with new diagnosis of MM as defined by:
- ICD-9-CM: 203.0x and/or ICD-10-CM: C90.0x or C90 during the study period
- At least two documented clinical visits for MM on different days and occurring on or after January 1, 2011
- Participants who received at least one systemic MM therapy on or after initial MM diagnosis
- Participants who did not receive clinical study drug at any time during the observation period
- Participants with race information
Exclusion
- Exclusion Criteria
- Patients with less than 6 months of medical data during the prior or follow-up period
- Patients in more than one race category (mix race), missing race, unknown race, and "other" race
- Patients diagnosed with the following hematological cancers on or prior to the index date:
- myelodysplastic syndromes (ICD-9: 238.74, 238.75; ICD-10: D46.xx)
- mantle cell lymphoma (ICD-9: 200.4x, ICD-10: C83.1x)
- follicular lymphoma (ICD-9: 202.0x, ICD-10: C82.xx)
- marginal zone lymphoma (ICD-9: 200.3x, ICD-10: C83.4x)
- Patients with evidence of skin hyperpigmentation (ICD-9: 709.00, 709.09; ICD-10: L81.0, L81.1, L81.4, L81.8) on or prior to the index date
- 00 Dyschromia, unspecified
- 09 Other dyschromia
- L81.0 Post inflammatory hyperpigmentation
- L81.1 Chloasma/melasma
- L81.4 Other melanin hyperpigmentation
- L81.8 Other specified disorders of pigmentation
Key Trial Info
Start Date :
October 1 2023
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
August 1 2024
Estimated Enrollment :
4204 Patients enrolled
Trial Details
Trial ID
NCT06160167
Start Date
October 1 2023
End Date
August 1 2024
Last Update
August 23 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Flatiron Health Oncology Database
New York, New York, United States, 10013